June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
Hairlessness in mammals is due to complex genetic changes in both genes and regulatory regions.
January 2021 in “Annals of translational medicine” YH0618 helped reduce skin and nail problems and fatigue in chemotherapy patients.
September 2012 in “Hair transplant forum international” The document concludes with the creation of a Hair Transplant Foundation after reviewing the early hair transplant techniques and discussions from a forum.
January 2023 in “Dermatologic Therapy” The new 5% minoxidil foam is as effective and safe as Rogaine® for treating hair loss in Chinese men.
7 citations,
April 2017 in “Dermatologic surgery” Hyaluronic acid fillers and combination treatments significantly improve facial defects from autoimmune diseases and are well-tolerated.
April 2021 in “Journal of Investigative Dermatology” Spironolactone safely and effectively treats hair loss in female scarring alopecia patients.
134 citations,
June 2005 in “Neuropsychopharmacology” GABRA2 gene variations impact alcohol response, and hair loss medication finasteride reduces some effects.
125 citations,
September 2019 in “Journal of Clinical Immunology” Foxp3 is crucial for regulatory T cell function, and targeting these cells may help treat immune disorders.
89 citations,
October 1996 in “Dermatologic Clinics” Alopecia areata is likely caused by a combination of genetic factors and immune system dysfunction, and may represent different diseases with various causes.
March 2024 in “Clinical and experimental dermatology” Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.
188 citations,
March 2018 in “Frontiers in Immunology” Regulatory T-cells are important for healing and regenerating tissues in various organs by controlling immune responses and aiding stem cells.
144 citations,
November 2020 in “Frontiers in immunology” Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
137 citations,
July 2004 in “Journal of The American Academy of Dermatology” Horizontally sectioned scalp biopsies are more reliable for diagnosing hair loss in women when three samples are taken instead of one.
122 citations,
November 1984 in “Journal of the American Academy of Dermatology” No single treatment is consistently effective for alopecia areata, and more research is needed.
44 citations,
September 2014 in “Cell Death & Differentiation” Tumor suppressors help control inflammation in cancer and restoring their function could lead to new treatments.
32 citations,
January 2017 in “Orphanet journal of rare diseases” FOXN1 gene mutations cause a rare, severe immune disease treatable with cell or tissue transplants.
15 citations,
April 2003 in “Journal of dermatology” Alopecia areata causes hair loss due to an immune attack on hair follicles, influenced by genetics and environment.
14 citations,
April 2020 in “Journal of Cosmetic Dermatology” QR678 treatments were more effective and comfortable for male hair loss than PRP treatments.
10 citations,
May 1983 in “International Journal of Dermatology” Some people with severe hair loss saw hair regrowth after a specific light and drug treatment.
6 citations,
August 1991 in “Pediatric Clinics of North America” The document concludes that various hair and scalp disorders in children have specific treatments and proper diagnosis is essential.
March 2021 in “Clin-Alert” The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
January 2019 in “Applied Organometallic Chemistry” The compound (NH4)2Mn0.17Cu0.83Cl4.2H₂O has a specific structure, shows weak magnetism at low temperatures, and undergoes phase changes at high temperatures.